Generic Cubicin Availability

Cubicin is a brand name of daptomycin, approved by the FDA in the following formulation(s):

CUBICIN (daptomycin - injectable;iv (infusion))

  • Manufacturer: CUBIST
    Approval date: September 12, 2003
    Strength(s): 500MG/VIAL [RLD]

Has a generic version of Cubicin been approved?

No. There is currently no therapeutically equivalent version of Cubicin available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cubicin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods for administration of antibiotics
    Patent 6,468,967
    Issued: October 22, 2002
    Inventor(s): Frederick B.; Oleson, Jr. & Francis P.; Tally
    Assignee(s): Cubist Pharmaceuticals, Incorporated
    The invention provides methods for administering a therapeutically effective amount of daptomycin while minimizing skeletal muscle toxicity. The methods provide daptomycin administration at a dosing interval of 24 hours or greater. This long dosing interval minimizes skeletal muscle toxicity and allows for higher peak concentrations of daptomycin, which is related to daptomycin's efficacy. The invention also provides methods of administering lipopeptide antibiotics other than daptomycin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of the lipopeptide antibiotic at a dosage interval that does not result in muscle toxicity. The invention also provides methods of administering quinupristin/dalfopristin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of quinupristin/dalfopristin at a dosage interval that does not result in muscle toxicity.
    Patent expiration dates:
    • September 24, 2019
      ✓ 
      Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
  • Methods for administration of antibiotics
    Patent 6,852,689
    Issued: February 8, 2005
    Inventor(s): Oleson, Jr.; Frederick B. & Tally; Francis P.
    Assignee(s): Cubist Pharmaceuticals, Inc.
    The invention provides methods for administering a therapeutically effective amount of daptomycin while minimizing skeletal muscle toxicity. The methods provide daptomycin administration at a dosing interval of 24 hours or greater. This long dosing interval minimizes skeletal muscle toxicity and allows for higher peak concentrations of daptomycin, which is related to daptomycin's efficacy. The invention also provides methods of administering lipopeptide antibiotics other than daptomycin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of the lipopeptide antibiotic at a dosage interval that does not result in muscle toxicity. The invention also provides methods of administering quinupristin/dalfopristin while minimizing skeletal muscle toxicity by administering a therapeutically effective amount of quinupristin/dalfopristin at a dosage interval that dos not result in muscle toxicity.
    Patent expiration dates:
    • September 24, 2019
      ✓ 
      Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
  • Daptomycin for the treatment of biofilm and catheter salvage
    Patent 8,003,673
    Issued: August 23, 2011
    Inventor(s): Alder; Jeffrey & Silverman; Jared & Mortin; Lawrence & Van Praagh; Andrew
    Assignee(s): Cubist Pharmaceuticals, Inc.
    Daptomycin can be used for biofilm treatment (particularly central venous catheter salvage for S. epidermidis infected catheters). Catheter salvage with daptomycin shows rapid cidality, activity against stationary phase bacteria, and penetration and activity in biofilms. The present inventions provide formulations, methods, and articles of manufacture useful for biofilm treatment or catheter salvage involving daptomycin. Particular formulations include daptomycin in lactated Ringer's solution having a rapid kill curve against the bacteria of the biofilm.
    Patent expiration dates:
    • September 4, 2028
      ✓ 
      Patent use: TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS
  • High purity lipopeptides
    Patent 8,058,238
    Issued: November 15, 2011
    Inventor(s): Kelleher; Thomas & Lai; Jan-Ji & DeCourcey; Joseph P. & Lynch; Paul & Zenoni; Maurizio & Tagliani; Auro
    Assignee(s): Cubist Pharmaceuticals, Inc.
    The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.
    Patent expiration dates:
    • November 28, 2020
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • High purity lipopeptides
    Patent 8,129,342
    Issued: March 6, 2012
    Inventor(s): Kelleher; Thomas J. & Lai; Jan-Ji & DeCourcey; Joseph P. & Lynch; Paul D. & Zenoni; Maurizio & Tagliani; Auro R.
    Assignee(s): Cubist Pharmaceuticals, Inc.
    The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.
    Patent expiration dates:
    • November 28, 2020
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Anhydro-and isomer-a-21978c cyclic peptides
    Patent RE39071
    Issued: April 18, 2006
    Inventor(s): Baker; Patrick J. & Debono; Manuel & Farid; Khadiga Z. & Molloy; R. Michael
    Assignee(s): Eli Lilly and Company
    Two new groups of A-21978C cyclic peptides, anhydro- and isomer-A21978C peptide derivatives, have antibacterial activity and are useful as intermediates. The two groups are prepared via transpeptidation of the parent cyclic peptides. Pharmaceutical formulations containing the new peptides as active ingredients and methods of treating infections caused by susceptible Gram-positive bacteria with the formulations are also provided. The invention also provides an antibacterial composition containing the new drug substance LY 146032 in substantially pure form.
    Patent expiration dates:
    • June 15, 2016
      ✓ 
      Patent use: METHOD FOR TREATING BACTERIAL INFECTION
      ✓ 
      Drug substance
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Questions about Atrial Fibrillation? Get answers from our expert. Watch Video

Close
Hide
(web4)